RP-3500: A Novel, Potent, and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors

por Roulston, Anne, Zimmermann, Michal, Papp, Robert, Skeldon, Alexander, Pellerin, Charles, Dumas-Bérube, Émilie, Dumais, Valerie, Dorich, Stéphane, Fader, Lee D., Fournier, Sara, Li, Li, Leclaire, Marie-Eve, Yin, Shou Yun, Chefson, Amandine, Alam, Hunain, Yang, William, Fugère-Desjardins, Chloe, Vignini-Hammond, Sabrina, Skorey, Kathryn, Mulani, Amina, Rimkunas, Victoria, Veloso, Artur, Hamel, Martine, Stocco, Rino, Mamane, Yael, Li, Zuomei, Young, Jordan T.F., Zinda, Michael, Black, W. Cameron
Publicado 2022